Trial Search Results
Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic
The purpose of this study is to investigate whether an empirically validated treatment for insomnia (CBT-I) administered early in the course of sleep disturbance can prevent insomnia disorder or lessen negative mental health outcomes in the wake of the COVID-19 crisis in adults.
Stanford is currently not accepting patients for this trial.
- Behavioral: Remote Cognitive Behavioral Therapy for Insomnia
- Age 18 years or older
- Access to the internet
- Subjective complaint of sleep disturbance (ISI ≥10) that began after March 1, 2020 or
the COVID-19 Pandemic (self-reported during DUKE Interview)
- Lives in the United States
- Presence of suicidal ideation representing high risk as measured by the
Sheehan-Suicide Tracking Scale (S-STS).
- Use of medication specifically prescribed for sleep disturbance and unwilling or
unable to discontinue more than one week prior to baseline data collection.
- Current or lifetime history of bipolar disorder or psychosis
- Current substance abuse or dependence
- Not able to verbalize understanding of involvement in research and provide written,
- Not fluent or literate in English
- Unstable pharmacotherapy for other mental health disorders
- Severe impediment to vision, hearing, and/or hand movement, likely to interfere with
the ability to complete assessments, or are unable and/or unlikely to follow study
- Working rotating shift that overlaps with 2400h
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study